in treatment resistant depression, and we are delighted that our Phase II trial is now enrolling patients," said Daniel Burch, MD, Chief Medical Officer of CeNeRx. "The new formulation of TriRima
has demonstrated excellent safety in multiple studies to date, and we believe that it has the potential to become the first agent to achieve the triple action efficacy of MAO inhibitor drugs without their limiting side effects."
The modified release formulation of TriRima has major advantages over the version used in earlier studies. In addition to displaying excellent pharmacokinetic properties, the dosing frequency has been reduced to one tablet administered once or twice daily.
"TriRima addresses a large unmet medical need -- currently a substantial proportion of patients with major depression do not receive adequate relief from their therapy," noted Barry Brand, Chief Executive Officer of CeNeRx. "TriRima has the potential to be the first option that provides these patients superior efficacy and a good safety profile as monotherapy, and we look forward to advancing the Phase II trial in the coming year."
CeNeRx will be presenting at the Biotech Showcase 2011 meeting at 11:00 AM PST on January 11. The conference is being held January 10-12, 2011 at the Parc 55 Wyndham, San Francisco. More information on the meeting can be found at www.ebdgroup.com/bts/index.php.
About CeNeRx BioPharmaCeNeRx is a privately held clinical-stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system. CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, is in Phase II development for treatment resistant depression. RIMAs may have efficacy advantages over current agents for depression and are expected to have a good safety profil
Page: 1 2 3 Related medicine technology :1
|SOURCE CeNeRx BioPharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)2
. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study3
. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)4
. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders5
. CeNeRx BioPharma Completes $13 Million Series C Financing6
. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine7
. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States8
. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma9
. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma10
. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma11
. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma